Altre lingue Voyager Therapeutics, Inc.

Azioni

VYGR

US92915B1061

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 29/04/2024			Variaz. 5gg	Var. 1 gen.
7,77 ^USD	+1,97%		+2,64%	-7,94%

02/04	Voyager Therapeutics, Inc. nomina Robin Swartz come Principale Contabile	CI
26/03	VOYAGER THERAPEUTICS, INC. : Guggenheim ribadisce il giudizio positivo sul titolo	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	22/04
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	16/04
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	16/04
Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer	02/04
Voyager Therapeutics, Inc. Announces CFO Changes	02/04
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	27/03
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	26/03
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) added to S&P Biotechnology Select Industry Index	18/03
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer	13/03
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer	13/03
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024	13/03
Voyager Therapeutics: Q4 Earnings Snapshot	28/02
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	28/02
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Voyager Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	27/02
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	26/02
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	26/02
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast	21/02
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research	20/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Voyager Therapeutics, Inc.

Azioni

VYGR

US92915B1061

Altre lingue

Filtri